Acquisitions pave the way to the patent cliff
This article was originally published in Scrip
Executive Summary
The largest players in the this year's Scrip 100 ranking continue to implement a range of strategies to shift emphasis away from blockbuster-centric growth models and ensure greater insulation from generic competition. Datamonitor's Simon King explores the Scrip 100.
You may also be interested in...
Is AstraZeneca Abbott's most likely merger partner?
Following the announcement on 19 October that Abbott Laboratories is to separate its prescription pharmaceutical unit from its other business units, speculation has turned to whether a rival big pharma player will make a move to acquire Abbott’s prescription portfolio, which is heavily focused on the anti-TNF biologic therapy Humira (Scripintelligence.com 20 October 2011).
What Viehbacher sees in Genzyme
Sanofi-Aventis's proposed acquisition of Genzyme, announced on 29 August, is a major acceleration of its diversification strategy, which has also seen the company building a presence in the consumer, generics and animal health markets. Simon King explains why Christopher Viehbacher, Sanofi's CEO, is wooing the industry's leading niche market player.